Pharmigene, Inc. (7595.TWO)
Taipei Exchange · TWD · Healthcare · Diagnostics & Research
NT$7.50 (-2.60%) as of
Key statistics
- Market cap
- 378.49M
- EPS (TTM)
- -1.04
- Dividend yield
- 0.00%
- 52-week range
- 5.90 – 11.85
- Beta
- 0.00
- Revenue (TTM)
- 187.88M
- Profit margin
- -27.82%
- Volume
- 10.30k
About Pharmigene, Inc.
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variations; whole-genome precision annotation platform; single-cell and spatial transcriptomics data analysis software; precise immune cell identification; automated tissue dissociator; and clinical HLA testing platform. The company was founded in 2005 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.